14.04.2015 SARTORIUS AG  DE0007165607

DGAP-Adhoc: SARTORIUS AG: Dynamic First Quarter | Forecast Revised Upwards


 
SARTORIUS AG / Key word(s): Development of Sales/Development of Sales 14.04.2015 14:55 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- In the first quarter of 2015, the Sartorius Group achieved sales growth of around 17% in constant currencies based on preliminary figures, reaching approximately EUR258 million in consolidated revenue (reported gain: around 27%). This growth was driven primarily by the Bioprocess Solutions Division. Due to the low prior-year revenue base, the company had expected above-average growth rates for this first quarter. Nevertheless, the gains supported by strong performance in all product segments were higher than projected at the beginning of the year. Based on the results of the first three months, Sartorius has revised its forecast upwards for the full year of 2015. Sales revenue in constant currencies is now expected to increase by approximately 6% to 9% (previous guidance: approx. 4% to 7%). Management projects that the company's underlying EBITDA margin in constant currencies will increase to around 22% (previous guidance: around 21.5%). Further information will be published as part of the company's first-quarter reporting activities on April 20, 2015. Goettingen, Germany, April 14, 2015 This ad hoc announcement contains statements about the future development of the Sartorius Group. The content of these statements cannot be guaranteed as they are based on assumptions and estimates that harbor certain risks and uncertainties. This is a translation of the original German-language ad hoc announcement. Sartorius shall not assume any liability for the correctness of this translation. The original German ad hoc announcement is the legally binding version. Furthermore, Sartorius reserves the right not to be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected. --------------------------------------------------------------------------- Information and Explaination of the Issuer to this News: Contact Petra Kirchhoff Vice President of Group Corporate Communications and IR +49 (0)551.308.1686 [email protected] 14.04.2015 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: SARTORIUS AG Weender Landstraße 94 - 108 37075 Göttingen Germany Phone: +49.(0)551-308.0 Fax: +49.(0)551-308.3289 E-mail: [email protected] Internet: www.sartorius.com ISIN: DE0007165607, DE0007165631 WKN: 716560 , 716563 Listed: Regulated Market in Frankfurt (Prime Standard), Hanover; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 1.404,57 1.566,03 1.826,97 2.335,66 3.449,22 4.174,70 3.395,70
EBITDA1,2 353,20 405,00 495,80 636,70 1.134,26 1.410,40 962,70
EBITDA-Marge3 25,15 25,86 27,14 27,26 32,89 33,78
EBIT1,4 219,36 298,61 335,66 456,11 903,16 1.070,00 503,90
EBIT-Marge5 15,62 19,07 18,37 19,53 26,18 25,63 14,84
Jahresüberschuss1 159,33 197,48 218,74 299,56 426,98 655,40 290,00
Netto-Marge6 11,34 12,61 11,97 12,83 12,38 15,70 8,54
Cashflow1,7 206,51 244,52 377,19 511,53 865,81 734,20 853,60
Ergebnis je Aktie8 2,11 2,56 3,06 4,37 8,08 9,57 4,94
Dividende8 0,51 0,61 0,35 0,70 1,25 1,43 0,45
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: -

INVESTOR-INFORMATIONEN
©boersengefluester.de
Sartorius ST
WKN Kurs in € Einschätzung Börsenwert in Mio. €
716560 209,000 Halten 18.266,98
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
34,26 39,23 1,01 48,06
KBV KCV KUV EV/EBITDA
7,76 18,33 5,38 21,38
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
1,43 0,73 0,35 28.03.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
18.04.2024 19.07.2024 17.10.2024 16.02.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-22,49% -19,18% -21,13% -33,33%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu SARTORIUS AG  ISIN: DE0007165607 können Sie bei EQS abrufen


Medtech , 716560 , SRT , XETR:SRT